REPLIMUNE GROUP, INC. Active Patents
14 granted patents the USPTO still lists as patented, newest filing first, as the USPTO Open Data Portal records them; the company is the first-named applicant. The application number opens the full record at Patent Center.
- 2024-05-21: Application 18670296; Invention ONCOLYTIC VIRUS STRAIN; Applicant Replimune Limited; Status Patented Case.
- 2023-09-06: Application 18462133; Invention MODIFIED ONCOLYTIC VIRUS; Applicant Replimune Limited; Status Patented Case.
- 2023-02-02: Application 18163837; Invention ENGINEERED VIRUS; Applicant Replimune Limited; Status Patented Case.
- 2022-08-04: Application 17817618; Invention ONCOLYTIC VIRUS STRAIN; Applicant Replimune Limited; Status Patented Case.
| Filed | Application | Invention | Applicant | Status | Granted | Patent | Published as | Inventor name | Inventor country | Examiner |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-21 | 18670296 | ONCOLYTIC VIRUS STRAIN | Replimune Limited | Patented Case | 2026-03-03 | 12564633 | US20240301365A1 | Robert Stuart Coffin | United Kingdom | LI, BAO Q |
| 2023-09-06 | 18462133 | MODIFIED ONCOLYTIC VIRUS | Replimune Limited | Patented Case | 2025-11-11 | 12465639 | US20240018488A1 | Robert Stuart Coffin | United Kingdom | LI, BAO Q |
| 2023-02-02 | 18163837 | ENGINEERED VIRUS | Replimune Limited | Patented Case | 2025-08-26 | 12397053 | US20230212531A1 | Robert Stuart Coffin | United Kingdom | LI, BAO Q |
| 2022-08-04 | 17817618 | ONCOLYTIC VIRUS STRAIN | Replimune Limited | Patented Case | 2024-07-02 | 12024724 | US20230130992A1 | Robert Coffin | United Kingdom | LI, BAO Q |
| 2022-08-03 | 17817245 | MODIFIED ONCOLYTIC VIRUS | Replimune Limited | Patented Case | 2025-11-04 | 12458696 | US20230203453A1 | Robert Coffin | United Kingdom | LI, BAO Q |
| 2021-02-01 | 17164635 | ENGINEERED VIRUS | Replimune Limited | Patented Case | 2024-07-30 | 12049647 | US20210254019A1 | Robert Stuart Coffin | United Kingdom | LI, BAO Q |
| 2020-12-14 | 17250205 | TREATMENT USING ONCOLYTIC VIRUS | REPLIMUNE LIMITED | Patented Case | 2026-07-21 | 12685767 | US20210252135A1 | Robert Stuart COFFIN | United Kingdom | NATARAJAN, MEERA |
| 2020-02-24 | 16799090 | MODIFIED ONCOLYTIC VIRUS | Replimune Limited | Patented Case | 2022-08-30 | 11427810 | US20200199542A1 | Robert S. Coffin | United Kingdom | LI, BAO Q |
| 2020-01-10 | 16740203 | ONCOLYTIC VIRUS STRAIN | Replimune Limited | Patented Case | 2022-10-18 | 11473063 | US20200208122A1 | Robert S. COFFIN | United Kingdom | LI, BAO Q |
| 2019-06-04 | 16466612 | ALTERED VIRUS | Replimune Limited | Patented Case | 2024-08-13 | 12059444 | US20190343903A1 | Robert Stuart COFFIN | United Kingdom | VAN DRUFF, SYDNEY |
| 2018-07-09 | 16068830 | Engineered Virus | REPLIMUNE LIMITED | Patented Case | 2021-03-16 | 10947513 | US20190032024A1 | Robert COFFIN | United Kingdom | LI, BAO Q |
| 2018-07-09 | 16068826 | Oncolytic Virus Strain | REPLIMUNE LIMITED | Patented Case | 2020-02-25 | 10570377 | US20190040366A1 | Robert COFFIN | United Kingdom | LI, BAO Q |
| 2018-07-09 | 16068823 | Use of an Oncolytic Virus for the Treatment of Cancer | REPLIMUNE LIMITED | Patented Case | 2020-04-21 | 10626377 | US20190022157A1 | Robert COFFIN | United Kingdom | LI, BAO Q |
| 2018-07-09 | 16068816 | Modified Oncolytic Virus | REPLIMUNE LIMITED | Patented Case | 2020-04-07 | 10612005 | US20190015466A1 | Robert COFFIN | United Kingdom | LI, BAO Q |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |